![Steven Bellon](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 688 365 $ al 31/07/2026
Steven F.
Bellon is Chief Scientific Officer at Foghorn Therapeutics, Inc. since 2022.
Dr. Bellon was Executive Director & Head-Structural Biology at Constellation Pharmaceuticals, Inc. from 2008 to 2016.
Dr. Bellon earned a doctorate from Massachusetts Institute of Technology in 1992 and an undergraduate degree from Haverford College in 1987.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 20/04/2026 | 151.957 ( 0,26 % ) | 688 365 $ | 31/07/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| FOGHORN THERAPEUTICS INC. | Director Técnico/Científico/I+D | 10/01/2022 |
| Empresas | Cargo | Fin |
|---|---|---|
| CONSTELLATION PHARMACEUTICALS, INC. | Director/Miembro de la Junta | 01/05/2016 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 4 |
|---|---|
Massachusetts Institute of Technology
 Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
Haverford College
 Haverford College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Constellation Pharmaceuticals, Inc.
 Constellation Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops novel drugs targeting regulators of epigenetic function | Health Technology |
Foghorn Therapeutics, Inc.
 Foghorn Therapeutics, Inc. BiotechnologyHealth Technology Discovers and develops novel drugs to treat cancer and other serious medical disorders | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
